Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Certican® (Everolimus) Against Cytomegalovirus Disease in Renal Transplant Patients (Certi-CMV)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00828503
Recruitment Status : Unknown
Verified August 2012 by Marcus Saemann, Medical University of Vienna.
Recruitment status was:  Recruiting
First Posted : January 26, 2009
Last Update Posted : September 3, 2012
Information provided by (Responsible Party):
Marcus Saemann, Medical University of Vienna